Melanoma Diagnostics | GenomeWeb

Melanoma Diagnostics

After reporting a 27 percent increase in its fiscal third quarter revenues, Myriad Genetics this week outlined three strategic directives for diversifying its revenue base, including growing sales of its existing tests in the US, launching new tests and companion diagnostics in a

In addition to a five-marker diagnostic test that the company plans to launch in the second half of 2011, Myriad is developing a second melanoma test that would gauge survival benefit.

Myriad will develop tests using genetic markers acquired from Melanoma Diagnostics.

Under the terms of the deal, Myriad will have commercialization rights to "all tests derived from the technology on a worldwide basis in exchange for upfront fees and contingent payments based upon the commercial success of the products."

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.